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Introduction {#sec1}
============

The risk of birth defects in the newborns of pregnant women with type 1 or type 2 pregestational diabetes mellitus (PGDM) was appreciably higher than the ones of the mother who never suffered from diabetes or gestational diabetes mellitus ([@bib6]). Actually, the frequency of anomalies in the nervous system is 2.7 times higher than the average of congenital malformations induced by hyperglycemia ([@bib7], [@bib21]). One of the reasons for the high incidence of congenital anomalies of the nervous system is that neurulation occurs at a very early developmental stage, during which embryos are vulnerable to external harmful factors ([@bib27], [@bib28]). The precise mechanism underlying the teratogenesis of the nervous system associated with diabetes is unclear partially because of the complexity. However, maternal hyperglycemia is regarded as a very important teratogen leading to congenital anomalies by generating excess reactive oxygen species (ROS) at the neurula stage ([@bib7], [@bib40]). In our previous study, we found that neuronal differentiation was suppressed and glial cell lineage differentiation was slightly promoted while it was usually accompanied by an excessive oxidation stress in the embryo brain of PGDM mice, which might lead to maternal hyperglycemia-induced neurodevelopmental defects ([@bib17]).

As an initial phase of nervous system development, neurulation refers to the morphogenetic process by which the neural tube forms in vertebrates. The development of the nervous system is precisely controlled by a complex series of spatiotemporally coordinated signaling pathways ([@bib5], [@bib8], [@bib34], [@bib38], [@bib42]). The cell fate toward two subpopulations of neuronal and astroglial cells will depend on the cell localization, in which cells respond to a spatial morphogen concentration ([@bib11]). The subpopulation of neuronal or glial lineage can be identified using their respective markers, for example, neurons can be determined by neurofilament protein, whereas astrocytes can be identified by glial fibrillary acidic protein (GFAP) ([@bib25]). As a potent neural factor, ciliary neurotrophic factor (CNTF) was originally identified as a crucial factor to maintain chicken neuron survival *in vitro* ([@bib1], [@bib36]). CNTF acts as one of the key neuropoietic cytokines, which concertedly modulate neuronal and glial cell differentiation and responses to exogenous stimuli ([@bib3]). Janus-activated kinase-signal transducer, activator of transcription (JAK-STAT) is the major signaling transduction pathway for these neuropoietic cytokines including CNTF to exert their function ([@bib3]).

ROS plays a crucial role in regulating the redox reactions in a variety of signaling pathways ([@bib13], [@bib22], [@bib30]). Excessive ROS generation is often associated with pathologic disorders because ROS act as primary and secondary messengers to promote cell death ([@bib13], [@bib22], [@bib30]), through damaging macromolecules such as proteins, lipids, and DNA ([@bib35]). Accumulating evidence suggests that excess ROS exert a teratogenic effect on developing embryos and fetuses, such as neurodevelopmental defects ([@bib37]). Obviously, a delicate balance between ROS production and detoxification is indispensible for maintaining normal cellular functions ([@bib18], [@bib32]). Nrf2 is a Cap\'n'Collar basic leucine zipper transcription factor that protects cells from oxidative or electrophilic stress by regulating cellular redox homeostasis ([@bib13], [@bib41]). In the presence of oxidative stress, Nrf2 eventually activates transcription by specifically binding to the antioxidant response element of its target gene promoters ([@bib29]). Heme oxygenase 1 (HO1) and NAD(P)H quinone oxidoreductase 1 (NQO1) have been identified as vital genes involved in regulating Nrf2 expression ([@bib16]). Keap1 is a principal repressor of Nrf2 via ubiquitination ([@bib15]).

Therefore, in this study, we mainly committed to exploring how hyperglycemia affects the self-renewal and differentiation of neural stem cells during embryo development, using the streptozotocin (STZ)-induced PGDM mouse model and numerous corresponding cell lines.

Results {#sec2}
=======

The Probability of Neurodevelopmental Defects Is Augmented in PGDM Mouse Fetuses {#sec2.1}
--------------------------------------------------------------------------------

A mouse model of PGDM was established by intraperitoneal injection of STZ ([Figure S1](#mmc1){ref-type="supplementary-material"}A), and the harvest timings were based on the consideration of key points during neurogenesis and gliogenesis. Blood glucose levels were monitored ([@bib14]) to verify that a mouse model of PGDM had been successfully created ([Figure S1](#mmc1){ref-type="supplementary-material"}B). PGDM fetal mice had lower body weights than the ones in control mice at embryonic day (E)12.5, E15.5, and E18.5 ([Figure S1](#mmc1){ref-type="supplementary-material"}C). The phenotypes of morphological abnormality in early developmental PGDM mouse fetuses were principally focused on nervous systems including encephalocele, spina bifida, anencephaly, and fetal resorption ([Figures S1](#mmc1){ref-type="supplementary-material"}D--S1H). Compared with the control, there totally were higher incidences of PGDM fetal abnormality ([Figure S1](#mmc1){ref-type="supplementary-material"}I), in which brain and spinal malformations occurred more frequently than others except for fetal resorption ([Figure S1](#mmc1){ref-type="supplementary-material"}J), suggesting that the diabetic mouse model was successfully established.

PGDM Influences the Molecular Switch of Neural Stem Cells toward Neurogenesis or Gliogenesis at Neural Tube Trunk during Mouse Embryonic Neural Development {#sec2.2}
-----------------------------------------------------------------------------------------------------------------------------------------------------------

The results showed that positive areas of the neuronal marker Tuj1 (β3-tubulin) and NF-M (neurofilament-medium chain) in both E15.5 and E18.5 PGDM fetal trunk neural tubes were significantly less than the ones in control mice, whereas the positive areas of glial cell marker GFAP were dramatically bigger than the ones in control mice, and the positive Olig2 (oligodendrocyte transcription factor 2) cell numbers were much more than the ones in E15.5 and E18.5 control mice, respectively ([Figures 1](#fig1){ref-type="fig"}A--1L and [S2](#mmc1){ref-type="supplementary-material"}A--S2J). Meanwhile, western blot and quantitative PCR data also indicated that NF-M and Tuj1 expression at both mRNA and protein levels decreased and GFAP expression was upregulated in both E15.5 and E18.5 PGDM mice compared with controls ([Figures 1](#fig1){ref-type="fig"}M--1P and 1M′--1N′), suggesting that the hyperglycemia in PGDM promoted the differentiation of neural stem cells toward glial cells and simultaneously inhibited the differentiation of neural stem cells into neurons ([Figure 1](#fig1){ref-type="fig"}Q). The results of E12.5 control and PGDM mouse embryos demonstrated that both NF-M- and Tuj1-labeled neuronal differentiation was also suppressed and the expression of GFAP was increased ([Figures S3](#mmc1){ref-type="supplementary-material"}A--S3L), suggesting that hyperglycemia-induced imbalance of neural differentiation occurs at an early stage of development. The observation was further verified by the results of *in vitro* primary culture of neural stem cells and differentiated cells (see the details in [Transparent Methods](#mmc1){ref-type="supplementary-material"}) as shown in [Figures S4](#mmc1){ref-type="supplementary-material"}A--S4M.Figure 1Determination of Crucial Gene Expression of Neuronal Differentiation in the Fetal Trunk Neural Tubes of PGDM Mice(A) A sketch illustrating the transverse section level of E12.5, E15.5, or E18.5 fetal trunk neural tubes.(B--I) Olig2 (red) and NF-M (green) double-immunofluorescent staining (B--E) or GFAP immunofluorescent staining (F--I) was performed on the transverse sections of E15.5 (B, C, F, and G) or E18.5 (D, E, H, and I) neural tubes from control (B, D, F, and H) and PGDM (C, E, G, and I) groups. All sections were counterstained with DAPI.(B′--I′) High-magnification images from the sites indicated by white squares in (B--I), respectively.(J--L) Bar charts showing the rate comparisons of NF-M^+^ areas (J), Olig2^+^ cells (K), and GFAP^+^ areas (L) between control and PGDM groups.(M, N, M′, and N') Western blot data showing the expression of NF-M, Tuj1, and GFAP in E15.5 (M) or E18.5 (N) control and PGDM mouse embryos at protein level, which were quantitatively analyzed in M′--N′.(O and P) Quantitative PCR data showing the expression of *NF-M*, *Tuj1*, *Olig2,* and *GFAP* in E15.5 (O) or E18.5 (P) control and PGDM mouse embryos at mRNA level.(Q) A model illustrating the imbalance of neural differentiation induced by hyperglycemia.For (J, K, and L), n = 6, for (M′, N′, O, and P), n = 3, t test, \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001. Data are represented as mean ± SEM. Scale bars, 500 μm in (B--I) and 100 μm in (B′--I′). See also [Figures S1--S4](#mmc1){ref-type="supplementary-material"}.

Immunofluorescent staining showed that expression of CNTF was suppressed in E15.5 PGDM mouse neural tube at trunk level compared with control ([Figures 2](#fig2){ref-type="fig"}A--2E); moreover, the expression of CT-1 (cardiotrophin-1) ([Figures 2](#fig2){ref-type="fig"}F--2J) and LIF (leukemia inhibitory factor) ([Figures 2](#fig2){ref-type="fig"}K--2O) was upregulated in E15.5 PGDM mouse neural tubes at trunk level compared with controls ([Figures 2](#fig2){ref-type="fig"}F--2O). Meanwhile, quantitative PCR ([Figure 2](#fig2){ref-type="fig"}P) and western blot ([Figures 2](#fig2){ref-type="fig"}Q and 2R) data displayed that *CNTF* expression was reduced, and CT-1, *LIF*, *interleukin-6* expression was increased in PGDM mice compared with controls at both mRNA and protein levels. These data suggest that CNTF plays an important role in hyperglycemia-induced imbalance of neurogenesis and gliogenesis during neural development ([Figure 2](#fig2){ref-type="fig"}S).Figure 2Determining Hyperglycemia-Induced Expression of CNTF, CT-1, and LIF in the Fetal Trunk Neural Tubes of PGDM Mice(A--D, F--I, and K--N) CNTF (A--D), CT-1 (F--I), or LIF (K--N) immunofluorescent staining was performed on the transverse sections of E15.5 trunk neural tubes from control (A, B, F, G, K, and L) and PGDM (C, D, H, I, M, and N) groups, in which (B, D, G, I, L, and N) were counterstained with DAPI.(B′, D′, G′, I′, L′, and N′) The high-magnification images from the sites indicated by white squares in (B, D, G, I, L, and N), respectively.(E, J, and O) Bar charts showing the rate comparisons of CNTF^+^ areas (E), CT-1^+^ areas (J), and LIF^+^ areas (O) between control and PGDM groups.(P) Quantitative PCR data showing the expression of *CNTF*, *CT-1*, *LIF,* and *interleukin* (*IL)-6* in E15.5 control and PGDM mouse embryos at mRNA level.(Q and R) Western blot data showing the expression of CT-1 in E15.5 control and PGDM mouse embryos at protein level (Q), which was quantitatively analyzed (R).(S) A sketch describing the mechanism of how hyperglycemia affects neural differentiation.For (E, J, and O), n = 6, for (P and R), n = 3, t test, \*\*p \< 0.01. Data are represented as mean ± SEM. Scale bars, 500 μm in (A--D, F--I, and K--N) and 100 μm in (B′, D′, G′, I′, L′, and N′).

PGDM Affects Neural Stem Cell Self-Renewal at Neural Tube Trunk during Mouse Embryonic Neural Development {#sec2.3}
---------------------------------------------------------------------------------------------------------

Next we focused on the potential effect of PGDM on neural stem cell self-renewal because CNTF has been known to be a key factor in all the developmental processes of nervous system ([@bib31]). The double-immunofluorescent staining of Sox2 (the marker for multipotent neural stem cells and essential transcription factor for maintaining self-renewal) and proliferating cell nuclear antigen (PCNA) was performed on transverse sections of neural tubes of E15.5 and E18.5 control and PGDM mouse embryos at trunk level ([Figures 3](#fig3){ref-type="fig"}A--3L), and results demonstrated that both the ratio of Sox2-positive cells in total cells ([Figures 3](#fig3){ref-type="fig"}M and 3N) and the ratio of Sox2/PCNA-co-positive cells ([Figures 3](#fig3){ref-type="fig"}O and 3P) in Sox2-positive cells significantly decreased in E15.5 and E18.5 PGDM mouse embryonic neural tubes compared with controls. Quantitative PCR data also verified the lower expression of *Sox2* at the mRNA level in both E15.5 and E18.5 PGDM mouse embryonic neural tubes compared with control ([Figures 3](#fig3){ref-type="fig"}Q and 3R). The primary culture of neural stem cells *in vitro* ([Figures 3](#fig3){ref-type="fig"}S--3U) showed that high glucose (25 mmol/L) could inhibit neurosphere frequency of occurrence and addition of CNTF in culture medium rescued the hyperglycemia-induced reduction ([Figure 3](#fig3){ref-type="fig"}V). A similar result was observed in measuring neurosphere sizes ([Figure 3](#fig3){ref-type="fig"}W). This suggests that diabetes mellitus does not only influence the neural precursor cell fates toward glial cells but also affects the neural stem cell self-renewal.Figure 3Assessing Hyperglycemia-Induced Self-Renewal of Neural Stem Cells Using *In Vivo* and *In Vitro* Models(A--L) Sox2 (red, A, D, G, and J) and PCNA (green, B, E, H, and K) double-immunofluorescent staining was performed on the transverse sections of E15.5 (A--F) or E18.5 (G--L) trunk neural tubes from control (A--C and G--I) and PGDM (D--F and J--L) groups, in which (C, F, I, and L) were merged ones from Sox2 and PCNA staining, and then counterstained with DAPI.(C′, F′, I′, and L') The high-magnification images from the sites indicated by white squares in (C, F, I, and L), respectively.(M--P) Bar charts showing the rate comparisons of Sox2-positive cells in total cells (M and N) or Sox2 and PCNA double-positive cells in total Sox2-positive cells (O and P) on the transverse sections between E15.5 (M and O) or E18.5 (N and P) control embryos and PGDM embryos.(Q and R) Quantitative PCR data showing the expression of *Sox2* in E15.5 (Q) or E18.5 (R) control and PGDM mouse embryos at mRNA level.(S--U) Representative bright-field images of *in vitro* cultured neurospheres exposed to 5.5 mmol/L D-glucose (S), 25 mmol/L D-glucose (T), or 25 mmol/L D-glucose with CNTF (U).(V and W) Bar charts showing the percentages of neurosphere frequency-of-occurrence (V) or neurosphere sizes (W) in 25 mmol/L D-glucose and 25 mmol/L D-glucose with CNTF of the neurosphere numbers or sizes in 5.5 mmol/L, which is regarded as 100%.(X) A model illustrating the influence of hyperglycemia on neural stem cell self-renewal.For (M--P) and (V--W), n = 6, for (Q and R), n = 3, ANOVA, least significance difference, Student-Newman-Keuls, and t test, \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001. Data are represented as mean ± SEM. Scale bars, 500 μm in (A--L) and (S--U) and 100 μm in (C′, F′, I′, and L′).

PGDM-Induced Neuronal Proliferation Inhibition and Glial Cell Proliferation Enhancement Contribute to the Imbalance between Neurogenesis and Gliogenesis {#sec2.4}
--------------------------------------------------------------------------------------------------------------------------------------------------------

Double-immunofluorescent staining of NF-M (neuronal marker) and Ki67 (cell proliferation marker) was performed on transverse sections of neural tubes of E15.5 and E18.5 control and PGDM mouse embryos at trunk level ([Figures 4](#fig4){ref-type="fig"}A--4D, 4A1--4D1, and 4A2--4D2). Our results demonstrated that the ratio of NF-M + Ki67-positive cells in NF-M-positive cells from both E15.5 ([Figure 4](#fig4){ref-type="fig"}I) and E18.5 ([Figure 4](#fig4){ref-type="fig"}J) mouse embryos was significantly reduced in PGDM mice compared with controls. Double-immunofluorescent staining of Olig2 (glial cell marker) and PCNA (cell proliferation marker) was performed on the transverse sections of neural tubes of E15.5 and E18.5 control and PGDM mouse embryos at trunk level ([Figures 4](#fig4){ref-type="fig"}E--4H, 4E1--4H1, and 4E2--4H2), and results demonstrated that the ratio of Olig2 + PCNA-positive cells in Olig2-positive cells from both E15.5 ([Figure 4](#fig4){ref-type="fig"}K) and E18.5 ([Figure 4](#fig4){ref-type="fig"}L) mouse embryos appreciably increased in PGDM mice compared with controls, indicating that neuronal proliferation was inhibited and glial cell proliferation was activated in diabetes mellitus mouse embryos.Figure 4Determination of Cell Proliferation in the Fetal Trunk Neural Tubes of PGDM Mice(A--D, A1--D1, A2--D2) Ki67 (red, A--D) and NF-M (green, A1--B1) double-immunofluorescent staining was performed on the transverse sections of E15.5 (A--A2 and B--B2) or E18.5 (C--C2 and D--D2) trunk neural tubes from control (A--A2 and C--C2) and PGDM (B--B2 and D--D2) groups, in which (A2--D2) were merged ones from Ki67 and NF-M staining, and then counterstained with DAPI.(A2′--D2′) The high-magnification images from the sites indicated by the white squares in (A2--B2), respectively.(E--H, E1--H1, and E2--H2) Olig2 (red, E--H) and PCNA (green, E1--H1) double-immunofluorescent staining was performed on the transverse sections of E15.5 (E--E2 and F--F2) or E18.5 (G--G2 and H--H2) trunk neural tubes from control (E--E2 and G--G2) and PGDM (F--F2 and H--H2) groups, in which (E2--H2) were merged ones from Olig2 and PCNA staining, and then counterstained with DAPI.(E2′--H2′) The high-magnification images from the sites indicated by white squares in (E2--H2), respectively.(I and J) Bar charts showing the rate comparisons of NF-M and Ki67 double-positive cells in total NF-M-positive cells on the transverse sections between E15.5 (I) or E18.5 (J) control embryos and PGDM embryos.(K and L) Bar charts showing the rate comparisons of Oligo2 and PCNA double-positive cells in total Oligo2-positive cells on the transverse sections between E15.5 (K) or E18.5 (L) control embryos and PGDM embryos.For (I--L), n = 6, t test, \*p \< 0.05, \*\*p \< 0.01. Data are represented as mean ± SEM. Scale bars, 500 μm in (A--H), (A1--H1), and (A2--H2) and 100 μm in (A2′--H2′).

PGDM Activates the Oxidative Stress and Nrf2 Signaling in Developing Mouse Neural Tubes, and Primary Culture of Neural Stem Cells and Differentiated Cells {#sec2.5}
----------------------------------------------------------------------------------------------------------------------------------------------------------

To investigate whether or not oxidative stress is involved in the PGDM-induced maladjustment of neural stem cell development, we determined the various indicators for oxidative stress. First, we found that intracellular ROS production was much higher in hyperglycemia (25 mmol/L)-treated primary cultures of neural stem cells than in the controls (5.5 mmol/L) ([Figures 5](#fig5){ref-type="fig"}A and 5B). Second, we performed Nrf2 immunofluorescent staining on the primary culture of neural stem cells ([Figures 5](#fig5){ref-type="fig"}C and 5D) and differentiated cells ([Figures 5](#fig5){ref-type="fig"}F and 5G) to detect whether the Nrf2 was activated in the differentiation process of the neural stem cells in PGDM mice. The results showed a higher expression of Nrf2 in the hyperglycemia-treated cells compared with the controls ([Figures 5](#fig5){ref-type="fig"}E and 5H). Transmission electronic microcopy manifested that the numbers of mitochondria (indicated by red arrows) in neural stem cells of PGDM neural tubes were much more than the ones in controls ([Figures 5](#fig5){ref-type="fig"}I--5K). Both quantitative PCR ([Figure 5](#fig5){ref-type="fig"}L) and western blot ([Figure 5](#fig5){ref-type="fig"}M) displayed that expression of *Nrf2*, *HO1*, *SOD2*, *NQO1*, and *p62* was upregulated in PGDM mouse neural tubes when compared with the ones in controls, implying that oxidative stress and Nrf2 signaling are indeed activated in PGDM embryos, which in turn might influence or promote other signaling pathways.Figure 5Assessing Hyperglycemia-Induced ROS and Oxidative Stress-Related Gene Expression Using *In Vivo* and *In Vitro* Models(A and B) ROS level in cultured neurospheres exposed to 5.5 mmol/L and 25 mmol/L D-glucose was detected using flow cytofluorometry (A), and then ROS production in 5.5 mmol/L and 25 mmol/L D-glucose groups was quantitatively analyzed (B).(C, D, C′, and D′) Nrf2 (red) immunofluorescent staining was performed on the neurospheres exposed to 5.5 mmol/L (C and C′) or 25 mmol/L D-glucose (D and D′), in which (C′ and D′) were counterstained with DAPI.(F, G, F′, and G') Nrf2 (red) immunofluorescent staining was performed on the differentiated cells exposed to 5.5 mmol/L (F and F′) or 25 mmol/L D-glucose (G and G′), in which (F′ and G′) were counterstained with DAPI.(E and H) Bar charts showing the comparisons of Nrf2-positive cells in total cells labeled by DAPI between 5.5 mmol/L and 25 mmol/L D-glucose groups.(I--K) The representative mitochondria images of neural progenitors taken by transmission electron microscope from the hippocampi of E15.5 control (I) and PGDM (J) embryos, in which mitochondria numbers were quantitatively analyzed (K). Arrows mark mitochondria.(L) Quantitative PCR data showing the expression of *Nrf2*, *HO1*, *SOD2*, *NQO1,* and *p62* in E18.5 control and PGDM mouse embryos at mRNA level.(M and N) Western blot data showing the expression of p62 in E18.5 control and PGDM mouse embryos at protein level (M), which was quantitatively analyzed (N).For (B, L, and N), n = 3, for (E, H, and K), n = 6, t test, \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001. Data are represented as mean ± SEM. Scale bars, 20 μm in (C, D, F, and G) and (C′, D′, F′, and G′) and 2 μm in (I and J).

Both CNTF and Nrf2 Can Affect Neural Stem Cell Differentiation in a High-Glucose Microenvironment {#sec2.6}
-------------------------------------------------------------------------------------------------

To further address the role of Nrf2 signaling in hyperglycemia-induced imbalance of neural precursors, we inspected the neuronal and glial cell markers in primary culture of differentiated cells in the absence or presence of CNTF when Nrf2 signaling was blocked with ML385 ([@bib33]). Initially, Nrf2 and NF-M double-immunofluorescent staining demonstrated that hyperglycemia induced the proportional reduction of Nrf2-positive neurons in total NF-M-positive cells compared with control ([Figures 6](#fig6){ref-type="fig"}A--6C), whereas Nrf2 and GFAP double-immunofluorescent staining demonstrated that hyperglycemia induced the proportional increase of Nrf2-positive glial cells in total GFAP-positive cells compared with controls ([Figures 6](#fig6){ref-type="fig"}D--6F), implying the vital role of Nrf2 in neural differentiation under hyperglycemic conditions. Next, we found that addition of CNTF alone could elevate the neuron proportion ([Figures 6](#fig6){ref-type="fig"}G--6H″ and 6Q), whereas hyperglycemia (25 mmol/L) significantly suppressed the neuron proportion ([Figures 6](#fig6){ref-type="fig"}I--6I″ and 6Q); the combinational application of hyperglycemia and CNTF could rescue the neuron proportional decrease induced by hyperglycemia ([Figures 6](#fig6){ref-type="fig"}J--6J″ and 6Q), but the recovery of neuron proportion disappeared again (even reduced more than solo hyperglycemia treated) when Nrf2 signaling was blocked with ML385 ([Figures 6](#fig6){ref-type="fig"}K--6K″ and 6Q). For the glial cells, we manifested that the addition of CNTF only could inhibit the glial cell proportion ([Figures 6](#fig6){ref-type="fig"}L--6M′ and 6Q), whereas hyperglycemia (25 mmol/L) promoted the glial cell proportion ([Figures 6](#fig6){ref-type="fig"}N--6N′ and 6Q); the combinational application of hyperglycemia and CNTF could pull down the glial cell proportion increase induced by hyperglycemia ([Figures 6](#fig6){ref-type="fig"}O--6O′ and 6Q), but the increase of glial cell proportion occurred again when Nrf2 signaling was blocked with ML385 ([Figures 6](#fig6){ref-type="fig"}P--6P′ and 6Q). These data undoubtedly indicate the crucial role of both CNTF and Nrf2 signaling in regulating the differentiation of neural stem cells in PGDM. To explore the cross talk of Nrf2 signaling and CNTF expression, we performed the CNTF immunofluorescent staining on the primary culture of differentiated cells *in vitro* ([Figure S5](#mmc1){ref-type="supplementary-material"}). The result showed that blocking Nrf2 with ML385 did not affect the CNTF expression level compared with the combined application of hyperglycemia and CNTF ([Figures S5](#mmc1){ref-type="supplementary-material"}A--S5F), implying that there is not direct interaction between Nrf2 and CNTF expression ([Figure S5](#mmc1){ref-type="supplementary-material"}G).Figure 6Determining Hyperglycemia-Induced Expression of Olig2, NF-M, and GFAP in Differentiated Cells when Adding CNTF or Blocking Nrf2(A--A″ and B--B″) Nrf2 (red, A and B) and NF-M (green, A′ and B′) double-immunofluorescent staining was performed on differentiated cells under 5.5 mmol/L (A and A″) or 25 mmol/L D-glucose (B and B″), in which (A″ and B″) were merged ones counterstained with DAPI.(C) Bar chart showing the rate comparisons of Nrf2 and NF-M double-positive cells in total Nrf2-positive cells.(D--D″ and E--E″) Nrf2 (red, D and E) and GFAP (green, D′ and E′) double-immunofluorescent staining was performed on differentiated cells under 5.5 mmol/L (D--D″) or 25 mmol/L D-glucose (E--E″), in which (D″--E″) were merged ones counterstained with DAPI.(F) Bar chart showing the rate comparisons of Nrf2 and GFAP double-positive cells in total Nrf2-positive cells.(G--K, G′--K′, and G″--K″) Oligo2 (red, G--K) and NF-M (green, G′--K′) double-immunofluorescent staining was performed on differentiated cells under 5.5 mmol/L D-glucose (G--G″), 5.5 mmol/L D-glucose + CNTF (H--H″), 25 mmol/L D-glucose (I--I″), 25 mmol/L D-glucose + CNTF (J--J″), and 25 mmol/L D-glucose + CNTF + ML385 (K--K″), in which (G″ and K″) were merged ones counterstained with DAPI.(L--P and L′--P') GFAP (red, L--P) immunofluorescent staining was performed on differentiated cells exposed to 5.5 mmol/L D-glucose (L--L″), 5.5 mmol/L D-glucose + CNTF (M--M″), 25 mmol/L D-glucose (N--N″), 25 mmol/L D-glucose + CNTF (O--O″), 25 mmol/L D-glucose + CNTF + ML385 (P--P″), in which (L′--P′) were merged ones counterstained with DAPI.(Q) Bar chart showing the rate comparisons of NF-M^+^, Olig2^+^, and GFAP^+^ cells in total cells labeled by DAPI among various groups.(R) A sketch illustrating the mechanism of how hyperglycemia affects neural differentiation.For (C, F, and Q), n = 6, ANOVA, least significance difference, Student-Newman-Keuls, and t test, \*p \< 0.05, \*\*p \< 0.01. Data are represented as mean ± SEM. Scale bars, 20 μm in (A--A″), (B--B″), (D--D″), (E--E″), (G--P), (G′--P′), and (G″--K″). See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

We then hypothesized that both Nrf2 and CNTF were regulating a key protein to affect the neural stem cell differentiation fate in a high-glucose microenvironment. To verify our hypothesis, we first checked the key molecules between Nrf2 signaling and neuropoietic cytokines using a bioinformatics approach ([Figure 7](#fig7){ref-type="fig"}A) ([@bib24]). From the result, we could find that Nrf2 signaling and neuropoietic cytokines are closely associated with STAT3. Therefore, Nrf2 and p-STAT3 double-immunofluorescent staining was performed on primary culture of differentiated cells ([Figures 7](#fig7){ref-type="fig"}B--7F″). The results showed that hyperglycemia caused an increase in Nrf2 expression and ML385 could significantly reverse the hyperglycemia-induced Nrf2 increase; whereas CNTF addition promoted the expression of p-STAT3, hyperglycemia (25 mmol/L) inhibited p-STAT3 expression. A combination of CNTF and high glucose could counteract hyperglycemia-inhibited p-STAT3 expression, but p-STAT3 expression was suppressed again when Nrf2 signaling was blocked with ML385 ([Figure 7](#fig7){ref-type="fig"}G), which certainly indicates that STAT3 is the important downstream molecule of Nrf2 signaling in the process of regulating neural self-renewal and differentiation during embryonic neural development in PGDM.Figure 7Determining Hyperglycemia-Induced Expression of Nrf2 and p-STAT3 in Differentiated Cells when Adding CNTF or Blocking Nrf2(A) Bioinformatics analysis depicting the correlation between Nrf2/keap1 signaling and STAT3 signal transduction pathway were mapped with the STRING database to construct the protein-protein interaction (PPI) network.(B--F, B′--F′, and B″--F″) Nrf2 (red, B--F) and p-STAT3 (green, B′--F′) double-immunofluorescent staining was performed on differentiated cells under 5.5 mmol/L D-glucose (B--B″), 5.5 mmol/L D-glucose + CNTF (C--C″), 25 mmol/L D-glucose (D--D″), 25 mmol/L D-glucose + CNTF (E--E″), and 25 mmol/L D-glucose + CNTF + ML385 (F--F″), in which (B″ and F″) were merged ones counterstained with DAPI.(G) Bar chart showing the rate comparisons of Nrf2^+^ and p-STAT3^+^ cells in total cells labeled by DAPI among various groups. n = 6, ANOVA, least significance difference, Student-Newman-Keuls, and t test, \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001. Data are represented as mean ± SEM. Scale bars, 20 μm in (B--F), (B′--F′), and (B″--F″).

Discussion {#sec3}
==========

In this study, we first confirmed the successful construction of a PGDM mouse model induced by STZ through the observation that blood glucose was kept at high level in PGDM mice after 3-day STZ injection ([Figures S1](#mmc1){ref-type="supplementary-material"}A--S1C). PGDM noticeably increased the incidence rate of mouse fetal developmental anomalies, including encephalocele, spina bifida, anencephaly, and fetal resorption ([Figures S1](#mmc1){ref-type="supplementary-material"}D--S1J). These phenotypes are mostly similar to the previous reports about neurodevelopmental defects in PGDM ([@bib23]). It is noteworthy that most of the fetuses of pregnant diabetic mouse did not manifest any obvious morphological anomalies in the nervous system. However, even in this case, the possibility that PGDM negatively influences fetal neurodevelopment cannot be excluded because hyperglycemia\'s influence on neurogenesis was not so serious to cause the appearance of morphological manifestations. It is just based on this consideration that we chose the E15.5 or E18.5 PGDM embryos that appear either normal or show subtle anomalies for further immunohistochemistry experiments. It has been reported that maternal diabetes can delay neurogenesis from E8.5 to E10 ([@bib39]), and here we mainly focus on the effect of hyperglycemia on cell fate decision of neural stem cells at later gestation stage in this study, so that we chose E12.5, E15.5, and E18.5 as time points. In the subsequent experiments, we demonstrated that the differentiation of neural stem cells toward NF-M- or Tuj1-labeled neuronal linkage was inhibited, but the differentiation toward Olig2 or GFAP-labeled glial cell linkage was promoted in both PGDM mouse embryos and *in vitro* model ([Figures 1](#fig1){ref-type="fig"} and [S2--S4](#mmc1){ref-type="supplementary-material"}), which is comparable to the report about diabetes-impaired neurogenesis reflected in neuronal proliferation, differentiation, and cell survival ([@bib10]).

In tracking the possible cause of PGDM-induced phenotypes, we found a downregulation of CNTF and upregulation of CT-1 and LIF in E15.5 PGDM mouse neural tubes compared with control mice ([Figure 2](#fig2){ref-type="fig"}). As we know, all CNTF, LIF, and CT-1 belong to the neuropoietic family ([@bib3]). CNTF is well known to be involved in normal nervous system development during embryogenesis, and it sequesters in adult glial cells and becomes activated or secreted again as a cytokine during injury ([@bib3]). It has been reported that CNTF inhibited lineage restriction of neural stem cells to glial progenitors, resulting in enhanced expansion of stem cell number ([@bib31]). CNTF administration can stimulate neurogenesis in the adult hippocampus and hypothalamus ([@bib12], [@bib19]). LIF is considered to reduce neurogenesis of neural stem cells ([@bib4]) and mediated astrogliogenesis in mouse embryos later than E15 ([@bib2]). CT-1 was generated in newly born neurons and controlled multipotent cortical precursors to differentiate into astrocytes, a neural feedback by an autocrine or paracrine mechanism ([@bib2]).

Therefore, the up- and downregulation of CT-1 and CNTF expression in the PGDM mouse could contribute to the promoted developmental switch toward gliogenesis during embryonic neurogenesis. Still, the spatiotemporal coordination of the neuropoietic cytokine family rather than one single alteration is indispensably emphasized, which is partially due to the developmental time difference between neurogenesis and gliogenesis. Our result suggests that the self-renewal of neural stem cells was suppressed by hyperglycemia ([Figure 3](#fig3){ref-type="fig"}). A neurosphere assay was employed to verify the above observation because it ([Figure S4](#mmc1){ref-type="supplementary-material"}) can offer a uniform *in vitro* platform of neural stem cells to determine self-renewal and differentiation of neural stem cells ([@bib26]). Actually, the fact that hyperglycemia inhibited neural stem cell proliferation was confirmed in the *in vitro* neurosphere assay, and addition of exogenous CNTF could partially rescue the cell proliferation inhibition induced by hyperglycemia, indicating again the key role of CNTF in neural stem cell self-renewal in PGDM mice ([Figures 3](#fig3){ref-type="fig"}S--3X). In addition, we also discovered that the differentiated neuronal cell proliferation in mouse neural tubes was repressed, and differentiated glial cell proliferation in mouse neural tubes was promoted by PGDM ([Figure 4](#fig4){ref-type="fig"}), which suggests that sensitivity toward hyperglycemia was different between differentiated neuronal cells and differentiated glial cells.

Oxidative imbalance has negative effects on neural stem cell self-renewal and differentiation by influencing the expression of important gene transcription factors during cell proliferation, migration, differentiation, and apoptosis ([@bib9]). Our study also indicated that hyperglycemia-induced oxidative stress directly or indirectly exerts effects on the embryonic neural stem or progenitor cells ([Figure 5](#fig5){ref-type="fig"}). p62 interacts with the Nrf2-binding site on Keap1, and overproduction of p62 competes with the interaction between Nrf2 and Keap1, resulting in stabilization of Nrf2 and transcriptional activation of Nrf2 target genes ([@bib20]). In this study, Nrf2 signaling specific activity and expression of p62 were significantly enhanced in PGDM or hyperglycemia groups, suggesting that Nrf2 plays a crucial role against the oxidative stress in this process. To confirm the prediction, we established the co-localization expression of neuron marker (NF-M) and Nrf2 using immunofluorescent staining in the primary culture of neural stem cells, and hyperglycemia inhibited Nrf2-positive neurons rather than glial cells ([Figures 6](#fig6){ref-type="fig"}A--6E). Fascinatingly, blocking Nrf2 transcription activity with ML385 could inhibit CNTF-promoted neuronal differentiation linkage, but re-raised CNTF-inhibited glial cell differentiation linkage in neurosphere assay ([Figures 6](#fig6){ref-type="fig"}G--6Q), implying that Nrf2-modulated oxidative stress is involved in neural differentiation from neural stem or progenitor cells. There was no alteration of CNTF expression when Nrf2 transcription activity was blocked ([Figures S5](#mmc1){ref-type="supplementary-material"}A--S5F), indicating that Nrf2 is directly involved in twisting the developmental switch from neurogenesis to gliogenesis instead of influencing CNTF indirectly in the presence of hyperglycemia ([Figures 6](#fig6){ref-type="fig"}R and [S5](#mmc1){ref-type="supplementary-material"}G). Bioinformatics also provides the correlation between Nrf2/keap1 signaling and the STAT3 signal transduction pathway ([Figure 7](#fig7){ref-type="fig"}A). One more robust evidence to support the view above is that addition of CNTF could promote p-STAT3 signaling in the presence of hyperglycemia, but blocking Nrf2 transcription activity with its inhibitor would lead to the reduction of the p-STAT3 signal transduction pathway ([Figures 7](#fig7){ref-type="fig"}B--7G), by which neuropoietic cytokines like CNTF control neural stem cell renewal and differentiation.

In sum, this study revealed the impact of PGDM on neural stem cell self-renewal and differentiation and the corresponding mechanisms responsible for these effects. We demonstrated that PGDM or hyperglycemia could inhibit neural stem cell self-renewal and twist the developmental switch from neurogenesis into gliogenesis during early embryo development. In this process, neuropoietic cytokine, CNTF, has a very important impact on the regulation of neural stem cell self-renewal and differentiation. Another vital mediator involved is Nrf2 signaling, which has been verified to be independently implicated in the regulation of cell survival and differentiation during neural development. At last, we proved that CNTF and Nrf2 are coordinately involved in regulating differentiation of neural stem cells through p-STAT3. This undoubtedly suggests an avenue for confronting PGDM-induced neurodevelopmental defects, although more precise cellular and molecular biological experiments might be required to further solidify the conclusion.

Limitations of the Study {#sec3.1}
------------------------

Although this study revealed that PGDM suppressed the self-renewal ability of neural progenitor cells and induced an imbalance between neurogenesis and gliogenesis, we did not address whether or not these phenotypes could result in changes neurological function, because neurofunctional assessments have not yet been performed. In addition, the development of the nervous system is complex and regulated by a series of more broadly signaling pathways, therefore, more precise cellular and molecular mechanisms need to be explored in future studies.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Data and Code Availability {#appsec1}
==========================

The data that support the findings of this study are available from the corresponding author upon reasonable request.
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